<output id="b3vhn"></output><listing id="b3vhn"><output id="b3vhn"></output></listing><p id="b3vhn"><delect id="b3vhn"><address id="b3vhn"></address></delect></p>
<pre id="b3vhn"></pre><p id="b3vhn"><delect id="b3vhn"><address id="b3vhn"></address></delect></p><pre id="b3vhn"><delect id="b3vhn"><listing id="b3vhn"></listing></delect></pre>

<output id="b3vhn"></output><pre id="b3vhn"></pre>
<output id="b3vhn"><menuitem id="b3vhn"></menuitem></output>
<p id="b3vhn"></p>
<p id="b3vhn"></p>

<pre id="b3vhn"><delect id="b3vhn"><listing id="b3vhn"></listing></delect></pre>
<p id="b3vhn"></p>

<p id="b3vhn"></p>

<p id="b3vhn"><delect id="b3vhn"></delect></p>
<p id="b3vhn"><output id="b3vhn"></output></p>
<p id="b3vhn"></p>
<pre id="b3vhn"><p id="b3vhn"><delect id="b3vhn"></delect></p></pre>
<pre id="b3vhn"></pre>

<p id="b3vhn"><menuitem id="b3vhn"></menuitem></p>

<pre id="b3vhn"><output id="b3vhn"><menuitem id="b3vhn"></menuitem></output></pre>

<p id="b3vhn"></p>

<noframes id="b3vhn"><p id="b3vhn"><menuitem id="b3vhn"></menuitem></p>

<p id="b3vhn"><menuitem id="b3vhn"></menuitem></p>

歡迎您訪問武漢艾美捷科技有限公司官方網站!
站點地圖 服務熱線:400-6800-868
  • 產品
  • 文章

AGENT BRAND

品牌專題

當前位置:首頁 > 品牌專題

PBL Assay Science:人IFN-β ELISA試劑盒

發布者:艾美捷科技    發布時間:2024-03-27     
分享到:

干擾素(Interferon,IFN)受體蛋白是宿主細胞分泌的一類細胞因子,可調節免疫應答。作為被發現的第一類細胞因子,它被命名為“干擾素”,因為這種蛋白質能夠干擾病毒的復制。當存在病原體時,通常由宿主細胞釋放干擾素,周圍未感染的細胞感知后激活適當的細胞防御機制,以便消除病原體。IFN細胞因子根據其結合的不同干擾素受體分為三種類型(I型、II型和III型);每種IFN細胞因子誘導一種特定的免疫反應。此外,IFN細胞因子介導信號會促進主要組織相容性I類和II類分子(MHC I,MHC II)的上調,并活化許多下游信號級聯,從而生成抗病毒防御機制。

IFN.png

干擾素β(Interferon beta,IFN-β,IFNb)是細胞中第一波細胞因子反應的一部分。病原體感染可導致干擾素調節因子3(IRF3)的激活,該因子以反式激活IFN-β基因轉錄。與其他干擾素相比,IFN-β在生物學上是獨特的,研究表明,與IFN-α相比,IFN-β具有重疊和不同的基因表達模式。似乎IFN-β以比其他I型IFN更高的親和力與I型IFN-受體結合,并且它還可以以不同的方式調節受體內化。此外,IFN-β長期以來一直被認為可以抑制病毒復制,作為身體先天抗病毒反應的一部分,并被用作治療多發性硬化癥(MS)和一些腫瘤的藥物。

IFN-β.png

 

我們推薦PBL Assay Science的高靈敏度的人IFN-β ELISA試劑盒,測量人血清、血漿和組織培養基中的IFN-β水平。作為PBL Assay Science在中國區域的代理商,艾美捷科技將為中國客戶提供全面的PBL Assay Science產品以及客戶訂制化服務。歡迎大家隨時聯系我們。

43693e5aa89b31e1c495fa5aa862e07e_1708304544691.png

 

產品貨號

產品名稱

樣本類型

41415

VeriKine-HS Human Interferon Beta Serum ELISA Kit

血清、血漿、組織培養基(TCM)

 

VeriKine HS人IFN-β ELISA試劑盒設計用于測量自身免疫性疾病血清、健康血清/血漿或組織培養基樣品中低水平或基礎水平的人IFN-β,LLOQ靈敏度為1.2 pg/ml。

該測定法適用于測量人類血清樣品中的商標治療分子。研究人員和臨床研究人員檢查a)IFN-β分子的藥代動力學,b)作為生物標志物的IFN-β,或c)作為TLR制劑或其他免疫反應調節劑活性的藥效學標志物的IFN-β,將發現這種免疫測定是一種重要的實驗室工具。

 

人IFN-β ELISA試劑盒貨號:41415

樣品類型

血清、血漿、組織培養基

特異性

人IFN-β

檢測范圍

Protocol A: 1.2 - 150 pg/ml(提高血清性能)

Protocol B: 2.3 - 150 pg/ml

靈敏度(LLOQ)

1.2 pg/ml

實驗時間

Protocol A: 3小時30分

Protocol B: 3小時

變異系數

Inter-Assay < 8%

Intra-Assay < 10%

Spike Recovery > 90% in Serum

標準曲線

IFN-β ELISA.png

 

引用文獻(Citations):

1. Lei, X. et al., (2024), "CD4+T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors", Cell Mol Immunol., PMID: 38383773, DOI: 10.1038/s41423-024-01133-1 (link)

2. Morihiro, K. et al., (2024), "RNA Oncological Therapeutics: Intracellular Hairpin RNA Assembly Enables MicroRNA-Triggered Anticancer Functionality", J Am Chem Soc. PMID: 38170469, DOI: 10.1021/jacs.3c09524 (link)

3. Rohilla, A. et al., (2023), "Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP", Micro Spectr., e0201223, PMID: 38095464, DOI: 10.1128/spectrum.02012-23 (link)

4. Smith, KER., et al.,  (2023), "A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanomia: safety, efficacy, and T cell responses", Front Immunol., 14:1279387, DOI: 10.3389/fimmun.2023.1279387 (link)

5. Grunhagel, B., et al., (2023), "Reduction of IFN-I Responses by Plasmacytoid Dendritic Cells in a Longitudinal Trans Men Cohort, iScience, DOI: 10.1016/j.isci.2023.108209 (link)

6. Nilsen, K.E., et al., (2023), "Peptide derived from SLAMF1 prevents TLR4-mediated inflammation in vitro and in vivo", Life Sci Alliance, 6(12):e202302164, PMID: 37788908, DOI: 10.26508/isa.202302164 (link)

7. Ullah, T.R. et al., (2023), "Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection", Nat Commun. 14(1):5666, PMID: 37723181, DOI: 10.1038/s41467-023-41381-9 (link)

8. Arbore, G. et al., (2023), "Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma", Cancer Res., CAN-23-0356, PMID: 37350667, DOI: 10.1158/0008-5472.CAN-23-0356 (link)

9. Rajamanickam, A. et al., (2022), "Restoration of dendritic cell homeostasis and Type I/Type III interferon levels in convalescent COVID-19 individuals, BMC Immunol., 23(1):51, PMID: 36289478, DOI: 10.1186/s12865-022-00526-z (link)

10. Nagaoka, N., et al., (2022), "Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection", Viruses, 14(7):1399, DOI: 10.3390/v14071399 (link)

11. Dickey, L. et al., (2022), HIV-1-induced type I IFNs promote viral latency in macrophages, J. Leukoc. Biol. PMID:35588262, DOI:10.1002/JLB.4MA0422-616R (link)

12. Steiner, A. et al., (2022), Deficiency in coatomer complex I causes aberrant activation of STING signalling, Nature Communications, 13:2321, PMID: 35484149, DOI: 10.1038/s41467-022-29946-6 (link)

13. Akoi, Y. et al., (2022), Evaluation of the Relationships between Intestinal Regional Lymph Nodes and Immune Responses in Viral Infections in Children, Int. J. Mol. Sci., 23:318, DOI: 10.3390/ijms23010318 (link)

14. Jablonska, A., et al.,  (2021), The TLR9 2848C/T Polymorphism Is Associated with the CMV DNAemia among HIV/CMV Co-Infected Patients, Cells, 10:2360, DOI: 10.3390/cells10092360, (link)

15. Dorgham, et al. (2021). Considering Personalized Interferon Beta Therapy for COVID-19. Antimicrobial Agents and Chemotherapy, 3 pgs. PMID: 21321205. (link)

16. Contoli, M. et al., (2021), Blood Interferon-a Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients, Front. Immunol., PMID: 33767713, DOI: 10.3389/fimmu.2021.648004 (link)

17. Terajima, H et al., (2021), N6-methyladenosine promotes induction of ADAR1-mediated A-to-I RNA editing to supress aberrant antiviral innate immune response, PLoS Biol., 19(7):e3001292, PMID:34324489 (link)

18. Blanco-Melo, D. et al., (2020), Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19, Cell, 181(5):1036, PMID: 32416070, DOI: 10.1016/j.cell.2020.04.026 (link)

19. Dubey, et al. (2020). Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1B and a poly-ARG interferon beta-1B analogue. International Journal of Pharmaceutics, 6 pgs. PMID: no PMID. (link)

 

看到這兒,您心動了嗎?馬上聯系小艾吧!

美國的PBL Assay Science(又名:Pestka Biomedical Laboratories, Inc.)成立于1990年,創始人Sidney Pestka被稱為“干擾素之父”,PBL Assay Science 作為干擾素和細胞因子蛋白和抗體以及預包裝的一流的干擾素和細胞因子免疫測定試劑盒的高質量制造商而享有盛譽。生產和銷售的高品質干擾素產品和生物標志物檢測試劑盒在很多高影響力出版物中都有引用,并已在具有挑戰性的樣本中進行了外部驗證。

PBL Assay Science提供各種干擾素亞型的蛋白,抗體和檢測試劑盒,如:IFN-Alpha(IFN-ɑ 2a,IFN-ɑ 2b,IFN-ɑ 5,IFN-ɑ 6,IFN-ɑ 7,IFN-ɑ 14,IFN-ɑ 16,IFN-ɑ 17......),IFN-Beta(IFN-β 1a,IFN-β 1b),IFN-Lambda(IFN-λ),IFN-Omega(IFN-ω),IFN-Gamma(IFN-γ)......


武漢艾美捷科技有限公司,簡稱艾美捷,擁有進出口資質和自己的國際物流,與國內外90余家知名的試劑、原料及技術服務供應商深度合作,是國內生物制藥企業、診斷企業、跨國藥企、各大高校院所采購平臺的首選定供應商。



相關文章
  • 高品質保障 成熟的生產研發技術
  • 高性價比 價宜質優,性價比高
  • 高效省心 從購買到使用,放心無憂
  • 安全運輸 完善的保護措施安全運輸

微信掃碼在線客服

微信咨詢

全國免費技術支持

400-6800-868

在線客服
无码国产在线视频2021|国产在线观看麻豆91精品免费|97超级人人免费碰碰频道|人间五月天国产精品|91人人妻人人澡人人爽秒播
<output id="b3vhn"></output><listing id="b3vhn"><output id="b3vhn"></output></listing><p id="b3vhn"><delect id="b3vhn"><address id="b3vhn"></address></delect></p>
<pre id="b3vhn"></pre><p id="b3vhn"><delect id="b3vhn"><address id="b3vhn"></address></delect></p><pre id="b3vhn"><delect id="b3vhn"><listing id="b3vhn"></listing></delect></pre>

<output id="b3vhn"></output><pre id="b3vhn"></pre>
<output id="b3vhn"><menuitem id="b3vhn"></menuitem></output>
<p id="b3vhn"></p>
<p id="b3vhn"></p>

<pre id="b3vhn"><delect id="b3vhn"><listing id="b3vhn"></listing></delect></pre>
<p id="b3vhn"></p>

<p id="b3vhn"></p>

<p id="b3vhn"><delect id="b3vhn"></delect></p>
<p id="b3vhn"><output id="b3vhn"></output></p>
<p id="b3vhn"></p>
<pre id="b3vhn"><p id="b3vhn"><delect id="b3vhn"></delect></p></pre>
<pre id="b3vhn"></pre>

<p id="b3vhn"><menuitem id="b3vhn"></menuitem></p>

<pre id="b3vhn"><output id="b3vhn"><menuitem id="b3vhn"></menuitem></output></pre>

<p id="b3vhn"></p>

<noframes id="b3vhn"><p id="b3vhn"><menuitem id="b3vhn"></menuitem></p>

<p id="b3vhn"><menuitem id="b3vhn"></menuitem></p>